The press conference followed the FDA and Reagan-Udall Foundation's public meeting on PTSD, which included discussions on psychedelic therapy.

Read more

The Sept. 6 hybrid public meeting, hosted by the Reagan-Udall Foundation for the FDA, drew experts, advocates and critics to discuss how to move forward advancing PTSD treatment. While the official agenda skirted the recent MDMA decision, public comments and a subsequent press briefing brought a spotlight back on the issue.

In the spring, the Reagan-Udall Foundation for the FDA held a series of roundtable discussions with invited stakeholders. These conversations focused on the Food Safety Modernization Act’s Requirements for Additional Traceability Records for Certain Foods, commonly known as the food traceability rule.

Read more

The Reagan-Udall Foundation for the Food and Drug Administration is a nonprofit organization that was created by Congress to advance the mission of the FDA. The Foundation held a meeting recently entitled “Advancing Treatments for Post-Traumatic Stress Disorder” to discuss efforts to accelerate the development of treatments for PTSD, including psychedelic therapies.

The discussion, hosted by the Reagan-Udall Foundation for the Food and Drug Administration, a nonprofit formed by Congress to support FDA, didn’t focus specifically on psychedelic-assisted therapies, but the topic nevertheless featured prominently—especially during a stakeholder comment session where most spoke in favor of wider access to MDMA and other emerging treatments.

On September 6, the Reagan-Udall Foundation for the Food and Drug Administration, an independent nonprofit created by Congress in 2007 to support the FDA’s mission, hosted a public meeting in Washington, DC, to discuss the latest advancements in post-traumatic stress disorder (PTSD) treatment. Psychedelics were high on the agenda.

Reagan Udall Foundation for the US Food and Drug Administration (FDA), a non-profit organization created by Congress, hosted the hybrid public meeting “Advancing Treatments for Post-Traumatic Stress Disorder” on September 6, 2024.

On Wednesday, the FDA issued a Constituent Update detailing efforts to enhance food traceability. Deputy Commissioner Jim Jones highlighted the FDA’s online resources regarding the Food Traceability Rule, as well as roundtables with the Reagan-Udall Foundation aimed at aiding industry implementation of the Rule. Insights from these discussions will be further explored in an upcoming public meeting on Oct. 7. Stakeholders are encouraged to participate and provide feedback through Oct. 25. For registration details and further information about attending the public meeting please visit the Foundation website.